GLP-1 News — Week of August 31, 2026
The GLP-1 stories that mattered this week — what happened, and what each one means for you if you're using or considering these medications. Every story links to its primary source, and nothing here is influenced by advertisers.
FDA approves Mounjaro to reduce major cardiovascular risk in high‑risk type 2 diabetes
Eli Lilly announced that the U.S. FDA has approved Mounjaro (tirzepatide) to reduce the risk of heart attack or stroke in adults with type 2 diabetes who already face high cardiovascular risk. This expands Mounjaro’s label beyond blood‑sugar control to include formal cardiovascular‑outcomes benefits, based on Lilly’s trial data submitted to FDA. (2026-08-28)
What this means for you: If you have type 2 diabetes and high cardiovascular risk, your clinician can now point to an official heart‑protection indication when prescribing Mounjaro, which typically makes insurer prior authorization and coverage arguments easier over time. Coverage changes will not be instant, so you should still expect case‑by‑case decisions in the near term and may need your prescriber to document your cardiovascular risk clearly.
Source: Reuters via UOL
Related on Metabolic Ledger: /drugs/ozempic-vs-mounjaro
Court backs FDA’s removal of GLP‑1s from the official drug shortage list
The U.S. Court of Appeals for the Fifth Circuit upheld a lower‑court ruling that rejected compounders’ challenge to FDA’s 2024 decision to remove branded GLP‑1 drugs from the federal drug shortage list. The appeals court found that the compounders had not shown legal harm from FDA’s action, effectively siding with the agency and closing this particular path for defending continued large‑scale compounding of semaglutide and tirzepatide under shortage exemptions. (2026-08-31)
What this means for you: If you rely on cheaper compounded semaglutide or tirzepatide, this ruling strengthens FDA’s hand to restrict those products now that brands are considered adequately supplied. You should be prepared for tighter enforcement and possible shutdowns at some compounders over the coming months, and it may be worth learning your pharmacy’s 503A or 503B status and planning how you would switch to an FDA‑approved brand if needed.
Source: BioWorld
Related on Metabolic Ledger: /regulatory/fda-compounding-cliff
Saxenda added as to be discontinued in U.S. shortage data, with January 2027 end date
The U.S. drug shortage listing for liraglutide (Saxenda) was updated to mark Novo Nordisk’s Saxenda 6 mg/mL injection as to be discontinued, with availability expected only until a planned U.S. discontinuation in January 2027. While some other liraglutide products remain available, this update confirms that Saxenda’s manufacture is being phased out. (2026-08-27)
What this means for you: If you are on Saxenda for weight management, you now have a hard deadline and should start talking with your prescriber during 2026 about switching to alternatives such as semaglutide or tirzepatide products. Expect new prior authorizations, possible dose‑titration adjustments, and changes in your out‑of‑pocket cost depending on which replacement drug your insurance prefers.
Source: Drugs.com
Related on Metabolic Ledger: /drugs/saxenda-vs-wegovy
GLP‑1 shortage snapshot: only Saxenda and Victoza still officially in shortage
An August 31 GLP‑1 Briefing update, based on the FDA Drug Shortage Database, reports that among nine tracked GLP‑1 medications, only Saxenda and Victoza remain on the official shortage list. Other major brands, including Ozempic, Wegovy, Mounjaro, and Zepbound, are no longer listed as in shortage, and the summary also notes earlier moves such as discontinuation plans for some Rybelsus tablet strengths. (2026-08-31)
What this means for you: If you are on Ozempic, Wegovy, Mounjaro, or Zepbound, this suggests that national‑level supply has largely normalized, so any trouble filling your prescription is more likely due to local pharmacy logistics or insurance limits than a true shortage. If you take Saxenda or Victoza, you should still expect intermittent supply problems and discuss backup prescriptions or timing of refills with your prescriber and pharmacy.
Source: GLP‑1 Briefing
Related on Metabolic Ledger: /cost/glp1-drug-shortage-guide
Compounded tirzepatide still far cheaper than Zepbound or Mounjaro, cost index shows
An updated GLP‑1 Watchdog analysis of 42 U.S. providers finds the lowest advertised compounded tirzepatide price around 119 dollars per month and a median near 239 dollars, compared with Lilly’s Zepbound and Mounjaro list or program prices above 1,000 dollars per month before savings cards. The report compares these cash prices using Lilly’s public pricing and savings‑program terms as benchmarks. (2026-08-29)
What this means for you: If you pay cash and cannot access brand‑name tirzepatide through insurance or manufacturer programs, compounded versions remain dramatically cheaper but come with greater regulatory and safety uncertainty. You should weigh the savings against risks by choosing pharmacies that clearly disclose their 503A or 503B status and sourcing, and by staying ready to switch to an FDA‑approved option if enforcement actions or supply changes cut off your compounded source.
Source: GLP‑1 Watchdog
Related on Metabolic Ledger: /cost/tirzepatide-cash-price
Global update: China reviews oral Wegovy as Mounjaro’s new heart label is highlighted
A Reuters health‑news roundup notes that China’s drug regulator has accepted Novo Nordisk’s application for an oral formulation of Wegovy and, in the same piece, flags the U.S. FDA’s new approval of Mounjaro to lower major cardiovascular events in high‑risk adults with type 2 diabetes. The item places both moves in the context of global expansion of GLP‑1 options and indications. (2026-08-29)
What this means for you: China’s review of oral Wegovy does not change your access in the U.S. yet, but it signals that oral GLP‑1s are becoming a core part of global obesity‑drug strategy, which could influence future pricing and supply as production scales. For you, the immediate actionable change remains that Mounjaro now has a formal heart‑risk‑reduction label, which your clinician can use to argue for coverage if you have high‑risk type 2 diabetes.
Source: Reuters via Devdiscourse
Related on Metabolic Ledger: /after-glp1/glp1-and-heart-health